Histone deacetylase inhibitors: emerging mechanisms of resistance.
about
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapyInhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancerA meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell linesExposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumorsHistone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Design and Evaluation of Tumor-Specific Dendrimer Epigenetic Therapeutics.Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.Butyrate histone deacetylase inhibitors.Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells.The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines.Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor TherapyComparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerLoss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.Phase I trial of a new schedule of romidepsin in patients with advanced cancers.Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.Toxicological and metabolic considerations for histone deacetylase inhibitors.HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review)Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers.The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines.Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.FK228 from Burkholderia thailandensis MSMB43.Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells.A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228
P2860
Q24609974-CCFE9A66-1BC8-41E7-BAEF-11340DB2AEB5Q28488474-1214F463-5F8C-4D05-944D-ABC0C81DCCE5Q28540936-80D9448C-BB7B-4006-8458-69F82808D905Q33570005-49DDB0CE-4876-4241-9FC0-1800232D5D49Q34372994-B00C25D0-3FFF-4964-90F8-92FAE45DD2D4Q34425201-6AF42702-2238-469F-9F0A-37509AD3EB53Q35434188-DD920EBD-1301-43D8-9ADB-23304992821CQ35908427-5B56B227-D6EE-4FC7-8A5D-7C253C3E438AQ36283075-E635771B-90A3-46C8-87B6-41895DEB6AFBQ36574546-451C322D-7F2D-459C-9B4F-ACC66A546E02Q36776566-5C7627C9-87D0-4FDB-B306-0CDB45038203Q36810416-6319F010-1196-4DB5-99AE-B4E1915AE63AQ36882942-78A21EFE-E853-4B92-BEBA-C563F0932BA7Q37093273-7A1539B8-A9BA-4418-B93C-C1AC47053767Q37505528-8C155789-BC36-4377-AC98-6EF0DA1B0E85Q37589239-AFC14154-5B69-4622-9AFC-D81D49C6138AQ37667088-92CFA737-756A-454D-8C1E-AD1665F4B4E5Q38042561-4149AA0D-9B1F-47A2-B751-EDBEB0F47BC7Q38071321-D9EB5FD9-676F-430C-9CE5-9387B5F13279Q38333926-488D3A03-4CF4-4678-92ED-5FCAA1CDB52DQ38459887-4818D108-853F-41CB-94C5-B6C83B81EA48Q38695555-8A8583D5-229E-42BA-8700-0D908EB9BB81Q38749473-696ED21F-086D-4B1F-96BC-C80D602BA6A1Q39268578-5BB6C25B-0C48-4066-A7C1-02E536871AACQ42323574-3C1AD82C-B213-4EDB-A692-C53AEAF55BECQ46251027-22606CBC-F5E4-48D8-8173-14F471A6F775Q48533275-2AB2ACE2-4D0A-4940-8EBC-571B94AB7D9FQ51484852-B491FFEC-616D-4CDC-B21D-FE5C2B2518ECQ52590685-ED9A52B7-BEDD-49FC-A440-38BBDC3F9364Q58700133-BAD13E8A-8AC2-4528-9AEB-8DAFF1C470E7
P2860
Histone deacetylase inhibitors: emerging mechanisms of resistance.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Histone deacetylase inhibitors: emerging mechanisms of resistance.
@ast
Histone deacetylase inhibitors: emerging mechanisms of resistance.
@en
type
label
Histone deacetylase inhibitors: emerging mechanisms of resistance.
@ast
Histone deacetylase inhibitors: emerging mechanisms of resistance.
@en
prefLabel
Histone deacetylase inhibitors: emerging mechanisms of resistance.
@ast
Histone deacetylase inhibitors: emerging mechanisms of resistance.
@en
P2093
P2860
P356
P1476
Histone deacetylase inhibitors: emerging mechanisms of resistance
@en
P2093
Arup R Chakraborty
Julian Bahr
Susan E Bates
Victoria Luchenko
Zhirong Zhan
P2860
P304
P356
10.1021/MP200329F
P407
P577
2011-10-07T00:00:00Z